CIRM Funded Clinical Trials

A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

Disease Area: 
Investigator:
CIRM Grant:
Award Value:
$19,919,449
Trial Sponsor:
ImmunoCellular Therapeutics
Trial Stage: 
Phase 3
Trial Status: 
Suspended
Targeted Enrollment:
414
ClinicalTrials.gov ID:
Details: 

Autologous dendritic cells charged with peptides derived from tumor-associated antigens to drive the formation of T cells that specifically target cancer stem cellsĀ 

Design: 

Randomized, double-blind study.

Goal: 

Registration-enabling Phase 3 trial. Safety. Efficacy - overall survival.

Status: 

This study has suspended participant recruitment.